First-Line Augmentation for Depression with Irritability and Mood Lability (Bipolar Ruled Out)
For unipolar depression with prominent irritability and mood lability where bipolar disorder has been definitively excluded, augment your current antidepressant with either aripiprazole or quetiapine as first-line options, with lithium as an alternative if atypical antipsychotics are contraindicated.
Rationale and Evidence Hierarchy
The presentation of depression with irritability and mood lability creates diagnostic complexity, but since bipolar disorder is ruled out, this represents treatment-resistant unipolar depression with prominent affective dysregulation. The evidence strongly supports specific augmentation strategies:
Primary Augmentation Options
Atypical Antipsychotics (Aripiprazole or Quetiapine):
- These agents demonstrate the most robust evidence for augmentation in treatment-resistant depression 1
- Aripiprazole shows significant efficacy (OR = 1.85; 95% CrI, 1.27-2.27) with more robust evidence than other options 1
- Quetiapine demonstrates even higher efficacy (OR = 1.92; 95% CrI, 1.39-3.13) 1
- Both agents specifically address irritability and affective instability beyond their antidepressant effects
- Recent meta-analysis confirms only six treatments had confidence intervals that didn't overlap with placebo, including aripiprazole and quetiapine 2
Important Caveat: Both agents carry significantly higher discontinuation rates due to side effects compared to placebo—quetiapine (OR = 3.85) and aripiprazole (OR = 2.51) 1. Monitor closely for metabolic effects, sedation, and akathisia.
Alternative Augmentation Strategy
Lithium:
- Shows significant efficacy (OR = 1.56; 95% CrI, 1.05-2.55) 1
- Particularly effective for irritability and mood instability in unipolar depression
- Meta-analyses consistently support lithium as first-line augmentation therapy after antidepressant monotherapy failure 3
- However, evidence is less robust than for atypical antipsychotics in recent analyses 1
- Requires laboratory monitoring (thyroid, renal function, lithium levels every 3-6 months) 4
- Higher tolerability concerns (OR = 2.30 for discontinuation) 1
Other Evidence-Based Options (Second-Tier)
Thyroid Hormone (T3):
- Demonstrates efficacy (OR = 1.84; 95% CrI, 1.06-3.56) but with less robust evidence 1
- One study showed no significant difference between T3 and lithium augmentation 3
- Consider if atypical antipsychotics and lithium are not tolerated
Bupropion or Buspirone:
- Moderate-quality evidence shows augmentation with bupropion decreases depression severity more than buspirone 5
- Lower discontinuation rates with bupropion compared to buspirone 5
- May be particularly useful for irritability, though evidence is less robust than atypical antipsychotics
Clinical Algorithm
First attempt: Add aripiprazole (start 2-5 mg, titrate to 10-15 mg) OR quetiapine (start 50 mg, titrate to 150-300 mg)
- Choose aripiprazole if sedation is problematic
- Choose quetiapine if insomnia or agitation is prominent
If atypical antipsychotics contraindicated or not tolerated: Add lithium (target level 0.6-1.0 mEq/L)
- Requires baseline labs: CBC, thyroid function, renal function, calcium, pregnancy test
- Monitor levels and labs every 3-6 months
If both fail or are contraindicated: Consider bupropion SR augmentation (150-300 mg) or T3 (25-50 mcg)
Trial duration: Allow 6-8 weeks at therapeutic doses before declaring treatment failure 4
Critical Pitfalls to Avoid
- Do not use mood stabilizers as monotherapy in unipolar depression—they are augmentation agents only
- Avoid antidepressant switching alone when irritability and mood lability are prominent; augmentation shows superior evidence 5, 1
- Do not assume bipolar disorder based solely on irritability and mood lability in the context of depression—but remain vigilant for any emerging hypomanic symptoms, particularly with antidepressant augmentation
- Monitor metabolic parameters closely with atypical antipsychotics: baseline and 3-month fasting glucose, lipids, BMI, then yearly 4
- Avoid polypharmacy creep—if augmentation fails, consider switching the base antidepressant rather than adding a third agent 5
The evidence consistently demonstrates that augmentation strategies outperform switching strategies alone for treatment-resistant depression with affective dysregulation 6, 5, 1.